Breadcrumb

MEDIA_REFRESH_DATA_PRESS_RELEASE

Media

U.S. News Room

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

Tue Dec 10 00:00:00 GMT-05:00 2024 NEW
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML
Mon Dec 09 00:00:00 GMT-05:00 2024 NEW
Daiichi Sankyo Statement on the Passing of Toshinori Agatsuma, PhD Download
Mon Dec 09 00:00:00 GMT-05:00 2024 NEW
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Download
Thu Dec 05 00:00:00 GMT-05:00 2024 NEW
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis Download
Mon Dec 02 00:00:00 GMT-05:00 2024 NEW
Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH Download
Fri Nov 22 00:00:00 GMT-05:00 2024
Daiichi Sankyo Joins with LabCentral Community as Platinum Sponsor Download
Wed Nov 13 00:00:00 GMT-05:00 2024
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS Download
Tue Nov 12 00:00:00 GMT-05:00 2024
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Download
Fri Nov 08 00:00:00 GMT-05:00 2024
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product Download
Wed Oct 30 00:00:00 GMT-05:00 2024
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Download
Showing 1 - 10 of 207 results.